 NEW YORK, Jan. 20, 2023 GLOBE NEWSWIRE Cellectis the Company Euronext Growth: ALCLS NASDAQ: CLLS, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it has amended certain financial terms of the 20 million convertible note issued by its partner, Cytovia Therapeutics, LLC ... The post Cellectis Amends 20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia T... 